Last reviewed · How we verify
RC148 plus Carboplatin and Paclitaxel
RC148 is a PD-L1 inhibitor combined with standard chemotherapy (carboplatin and paclitaxel) to enhance anti-tumor immune response while providing cytotoxic chemotherapy.
RC148 is a PD-L1 inhibitor combined with standard chemotherapy (carboplatin and paclitaxel) to enhance anti-tumor immune response while providing cytotoxic chemotherapy. Used for Advanced or metastatic solid tumors (in combination with carboplatin and paclitaxel).
At a glance
| Generic name | RC148 plus Carboplatin and Paclitaxel |
|---|---|
| Also known as | RC148 plus Platinum-Based Chemotherapy |
| Sponsor | RemeGen Co., Ltd. |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
RC148 blocks the PD-L1 checkpoint, preventing tumor cells from suppressing T-cell activity, thereby restoring anti-tumor immunity. When combined with carboplatin and paclitaxel chemotherapy, the regimen aims to provide both direct cytotoxic effects and enhanced immunological tumor control. This combination approach is designed to improve efficacy in solid tumors resistant to single-agent therapy.
Approved indications
- Advanced or metastatic solid tumors (in combination with carboplatin and paclitaxel)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Fatigue
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
Key clinical trials
- A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC (PHASE1)
- RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RC148 plus Carboplatin and Paclitaxel CI brief — competitive landscape report
- RC148 plus Carboplatin and Paclitaxel updates RSS · CI watch RSS
- RemeGen Co., Ltd. portfolio CI